NorthStar Medical Radioisotopes has inked a nonexclusive letter of intent with radiopharmacy chain Triad Isotopes in hopes of bringing a domestic source of molybdenum-99 (Mo-99) to the U.S. market.
Under the deal, NorthStar will work with Triad to commercialize nonuranium-based Mo-99 produced with its RadioGenix isotope separation system. Triad will buy and lease the products once the technology has been approved by the U.S. Food and Drug Administration (FDA).
